SCHEMBL5835112

SCHEMBL5835112

COc1ccc(-c2nc3cc(-c4ccc(Cl)cc4Cl)ccc3o2)cc1N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.50
HPSE Q9Y251 3/20 0.49
PTGS2 P35354 4/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
HPGD P15428 1/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
RXFP1 Q9HBX9 1/20 0.46
NPC1 O15118 2/20 0.46
TP53 P04637 3/20 0.46
THRB P10828 3/20 0.46
RAB9A P51151 1/20 0.45
MAPT P10636 2/20 0.45
PTPN2 P17706 1/20 0.45
PTPN1 P18031 1/20 0.45
PTPN5 P54829 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5834587 0.90 LMNA (0.59) ALOX5HPSEPTGS2SMN1; SMN2KDM4E
SCHEMBL5834837 0.88 ALOX5 (0.55) ALOX5HPSEPTGS2SMN1; SMN2KDM4E
SCHEMBL6634807 0.87 ALOX5 (0.50) ALOX5HPSEPTGS2SMN1; SMN2KDM4E
SCHEMBL5834204 0.84 HPSE (0.56) ALOX5HPSEPTGS2SMN1; SMN2KDM4E
SCHEMBL5834473 0.84 ALOX5 (0.54) ALOX5HPSEPTGS2SMN1; SMN2KDM4E
SCHEMBL5834845 0.84 PTGS2 (0.53) ALOX5HPSEPTGS2SMN1; SMN2KDM4E
SCHEMBL5834548 0.83 ALOX5 (0.51) ALOX5HPSEPTGS2SMN1; SMN2KDM4E
SCHEMBL5835127 0.83 ALOX5 (0.50) ALOX5HPSEPTGS2SMN1; SMN2RXFP1
SCHEMBL5834540 0.83 NPC1 (0.56) ALOX5HPSEPTGS2SMN1; SMN2ALDH1A1
SCHEMBL5834972 0.82 ALOX5 (0.55) ALOX5HPSEPTGS2SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7138425-B2 Phthalimide carboxylic acid derivatives OXFORD GLYCOSCIENCE (UK) LTD. (GB) 2006-11-21 US disclosed
US-20050203153-A1 Phthalimide carboxylic acid derivatives OXFORD GLYCOSCIENCE (UK) LTD. (GB) 2005-09-15 US disclosed
EP-1483261-A1 PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES Oxford GlycoSciences (UK) Ltd, Attn: Mary Gadsden (GB) 2004-12-08 EP disclosed
WO-2003074516-A1 PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES OXFORD GLYCOSCIENCES (UK) LTD (GB) 2003-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203153-A1 Phthalimide carboxylic acid derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, IDH1 ALOX5 1038/4885HPSE 2626/4885PTGS2 1244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.